Skip to content

Study · Measured the body's own peptide · 2013

3 results

Inducible depletion of cardiac thymosin β4 : development and shortcomings of a popular technique in cardiac research

Lexow JM

Imperial College London1 Jan 2013

DOI10.25560/11091 (opens in a new tab)PepBankPUB-94667870
Source linkSource pageAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Natural levels measured3

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 01AnimalEndogenous levelAnimal study (in vivo)Mechanism

    In inducible Tβ4 knockdown mice, tamoxifen treatment did not significantly down-regulate Tβ4 mRNA in the heart.

    In plain wordsIn mice built to lose their own Tβ4, tamoxifen did not clearly lower Tβ4 gene activity in the heart.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    No significant changeCardiac Tβ4 mRNA after tamoxifen in knockdown mice
    Study

    mousen: not reported in source

    Tβ4shRNAflox/MerCreMer mice
    Outcome group
    Heart function · Cardiovascular

    Source sentences

    Summary
    tamoxifen treatment of Tβ4shRNAflox/MerCreMer mice does not result in significant down-regulation of Tβ4 mRNA or protein in the heart.
    1 context sentence
    Summary · context
    Tβ4shRNAflox/MerCreMer mice were generated with the aim of depleting cardiac Tβ4 expression by RNA interference in a tamoxifen-dependent fashion.

    This result measures the body's own Thymosin beta-4 (human). Nobody was given the peptide. It is not evidence about taking it.

  2. 02AnimalEndogenous levelAnimal study (in vivo)Mechanism

    In inducible Tβ4 knockdown mice, tamoxifen treatment did not significantly down-regulate Tβ4 protein in the heart.

    In plain wordsIn mice built to lose their own Tβ4, tamoxifen did not clearly lower Tβ4 protein in the heart.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    No significant changeCardiac Tβ4 protein after tamoxifen in knockdown mice
    Study

    mousen: not reported in source

    Tβ4shRNAflox/MerCreMer mice
    Outcome group
    Heart function · Cardiovascular

    Source sentences

    Summary
    tamoxifen treatment of Tβ4shRNAflox/MerCreMer mice does not result in significant down-regulation of Tβ4 mRNA or protein in the heart.
    1 context sentence
    Summary · context
    Tβ4shRNAflox/MerCreMer mice were generated with the aim of depleting cardiac Tβ4 expression by RNA interference in a tamoxifen-dependent fashion.

    This result measures the body's own Thymosin beta-4 (human). Nobody was given the peptide. It is not evidence about taking it.

  3. 03AnimalEndogenous levelAnimal study (in vivo)Mechanism

    In mouse hearts, Tβ4 levels were higher in cardiac fibroblasts than in cardiomyocytes.

    In plain wordsIn mice, the body's own Tβ4 levels were higher in heart fibroblasts than in heart muscle cells.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    IncreaseTβ4 level in cardiac fibroblasts versus cardiomyocytes
    Study

    mousen: not reported in source

    mouse heart cells
    Comparator
    Cardiomyocytes
    Outcome group
    Heart function · Cardiovascular

    Source sentences

    Summary
    Interestingly, higher levels of Tβ4 were identified in cardiac fibroblasts compared to cardiomyocytes.
    1 context sentence
    Summary · context
    Tβ4shRNAflox/MerCreMer mice were generated with the aim of depleting cardiac Tβ4 expression by RNA interference in a tamoxifen-dependent fashion.

    This result measures the body's own Thymosin beta-4 (human). Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 01:52 UTC

    Study results updated

  2. Version 1

    12 Oct 2026, 18:17 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.